Literature DB >> 18983167

Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity.

Huanchen Wang1, Zier Yan, Serena Yang, Jiwen Cai, Howard Robinson, Hengming Ke.   

Abstract

Cyclic nucleotide phosphodiesterase-8 (PDE8) is a family of cAMP-specific enzymes and plays important roles in many biological processes, including T-cell activation, testosterone production, adrenocortical hyperplasia, and thyroid function. However, no PDE8 selective inhibitors are available for trial treatment of human diseases. Here we report kinetic properties of the highly active PDE8A1 catalytic domain prepared from refolding and its crystal structures in the unliganded and 3-isobutyl-1-methylxanthine (IBMX) bound forms at 1.9 and 2.1 A resolutions, respectively. The PDE8A1 catalytic domain has a K(M) of 1.8 microM, V(max) of 6.1 micromol/min/mg, a k(cat) of 4.0 s(-1) for cAMP, and a K(M) of 1.6 mM, V(max) of 2.5 micromol/min/mg, a k(cat) of 1.6 s(-1) for cGMP, thus indicating that the substrate specificity of PDE8 is dominated by K(M). The structure of the PDE8A1 catalytic domain has similar topology as those of other PDE families but contains two extra helices around Asn685-Thr710. Since this fragment is distant from the active site of the enzyme, its impact on the catalysis is unclear. The PDE8A1 catalytic domain is insensitive to the IBMX inhibition (IC(50) = 700 microM). The unfavorable interaction of IBMX in the PDE8A1-IBMX structure suggests an important role of Tyr748 in the inhibitor binding. Indeed, the mutation of Tyr748 to phenylalanine increases the PDE8A1 sensitivity to several nonselective or family selective PDE inhibitors. Thus, the structural and mutagenesis studies provide not only insight into the enzymatic properties but also guidelines for design of PDE8 selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983167      PMCID: PMC2646200          DOI: 10.1021/bi801487x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  60 in total

Review 1.  Remembrance of things PAS: regulation of development by bHLH-PAS proteins.

Authors:  S T Crews; C M Fan
Journal:  Curr Opin Genet Dev       Date:  1999-10       Impact factor: 5.578

2.  T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3.

Authors:  N A Glavas; C Ostenson; J B Schaefer; V Vasta; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

3.  Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans.

Authors:  Michiko Gamanuma; Keizo Yuasa; Takashi Sasaki; Naoki Sakurai; Jun Kotera; Kenji Omori
Journal:  Cell Signal       Date:  2003-06       Impact factor: 4.315

4.  Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

Authors:  S H Soderling; S J Bayuga; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

5.  Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution.

Authors:  P Wang; P Wu; R W Egan; M M Billah
Journal:  Gene       Date:  2001-12-12       Impact factor: 3.688

6.  Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene.

Authors:  Masaaki Hayashi; Yasuhito Shimada; Yuhei Nishimura; Takaaki Hama; Toshio Tanaka
Journal:  Biochem Biophys Res Commun       Date:  2002-10-11       Impact factor: 3.575

7.  Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases.

Authors:  P Wang; P Wu; J G Myers; A Stamford; R W Egan; M M Billah
Journal:  Life Sci       Date:  2001-03-16       Impact factor: 5.037

Review 8.  Molecular diversity of cyclic AMP signalling.

Authors:  F A Antoni
Journal:  Front Neuroendocrinol       Date:  2000-04       Impact factor: 8.606

Review 9.  Phosphodiesterase 5 inhibitors: current status and potential applications.

Authors:  David P Rotella
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

Review 10.  The pharmacology of cilostazol.

Authors:  Karsten Schrör
Journal:  Diabetes Obes Metab       Date:  2002-03       Impact factor: 6.577

View more
  31 in total

1.  Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.

Authors:  Manna Huang; Yongxian Shao; Jianying Hou; Wenjun Cui; Beibei Liang; Yingchun Huang; Zhe Li; Yinuo Wu; Xinhai Zhu; Peiqing Liu; Yiqian Wan; Hengming Ke; Hai-Bin Luo
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

2.  Channeling of cAMP in PDE-PKA Complexes Promotes Signal Adaptation.

Authors:  Nikhil Kumar Tulsian; Srinath Krishnamurthy; Ganesh Srinivasan Anand
Journal:  Biophys J       Date:  2017-06-20       Impact factor: 4.033

3.  A phosphodiesterase 2A isoform localized to mitochondria regulates respiration.

Authors:  Rebeca Acin-Perez; Michael Russwurm; Kathrin Günnewig; Melanie Gertz; Georg Zoidl; Lavoisier Ramos; Jochen Buck; Lonny R Levin; Joachim Rassow; Giovanni Manfredi; Clemens Steegborn
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

4.  Atrazine acts as an endocrine disrupter by inhibiting cAMP-specific phosphodiesterase-4.

Authors:  Marek Kucka; Kristina Pogrmic-Majkic; Svetlana Fa; Stanko S Stojilkovic; Radmila Kovacevic
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-27       Impact factor: 4.219

5.  Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13.

Authors:  Junli Liu; Hongguang Xia; Minsu Kim; Lihua Xu; Ying Li; Lihong Zhang; Yu Cai; Helin Vakifahmetoglu Norberg; Tao Zhang; Tsuyoshi Furuya; Minzhi Jin; Zhimin Zhu; Huanchen Wang; Jia Yu; Yanxia Li; Yan Hao; Augustine Choi; Hengming Ke; Dawei Ma; Junying Yuan
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

6.  Somatic amplifications and deletions in genome of papillary thyroid carcinomas.

Authors:  Nadia Passon; Elisa Bregant; Marialuisa Sponziello; Maria Dima; Francesca Rosignolo; Cosimo Durante; Marilena Celano; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2015-04-12       Impact factor: 3.633

7.  PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.

Authors:  Marialuisa Sponziello; Antonella Verrienti; Francesca Rosignolo; Roberta Francesca De Rose; Valeria Pecce; Valentina Maggisano; Cosimo Durante; Stefania Bulotta; Giuseppe Damante; Laura Giacomelli; Cira Rosaria Tiziana Di Gioia; Sebastiano Filetti; Diego Russo; Marilena Celano
Journal:  Endocrine       Date:  2015-04-03       Impact factor: 3.633

8.  Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain.

Authors:  Zier Yan; Huanchen Wang; Jiwen Cai; Hengming Ke
Journal:  Protein Expr Purif       Date:  2008-10-19       Impact factor: 1.650

Review 9.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

10.  Interactions between cyclic nucleotide phosphodiesterase 11 catalytic site and substrates or tadalafil and role of a critical Gln-869 hydrogen bond.

Authors:  James L Weeks; Jackie D Corbin; Sharron H Francis
Journal:  J Pharmacol Exp Ther       Date:  2009-07-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.